U

Levation Pharma

Topical Oxymetazoline for Cosmetic Eye Lifts
Startup Seed Founded 2017 Health Tech & Life Sciences
Last Update Mar 19, 2024

Levation Pharma News

1 article
Feb 26, 2023 · www.globenewswire.com
Growth-Positive
Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Levation Pharma, a pharmaceutical company specializing in ophthalmology and aesthetic therapeutics, has received FDA clearance to initiate a Phase I/II clinical trial for LEV102, a treatment for Acquired Blepharoptosis in adults. The condition, characterized by drooping of the upper eyelid, can impair vision and give an appearance of aging and tiredness. LEV102 is a proprietary aqueous gel that includes oxymetazoline as the active ingredient, intended to activate receptors on Mueller’s muscle in the upper lid. The clinical trial aims to determine preliminary safety and efficacy signals for LEV102. Levation Pharma is an Israeli-American company based in Los Angeles and is backed by venture firms Pontifax and Peregrine.
Investment